Kiernan et al. posited that combined therapy was superior to standard anti-VEGF treatment in cases of exudative AMD unresponsive to standard treatment, reducing the number of intravitreal injections and stabilizing or improving visual acuity [157]. This evidence concerns the gene VEGFA and age-related macular degeneration.